课题基金 / 基金详情

14th International Conference on HIV Treatment, Pathogenesis, and Prevention Research (INTEREST)

14th International Conference on HIV Treatment, Pathogenesis, and Prevention Research (INTEREST)
第14届国际艾滋病毒治疗、发病机制和预防研究会议(INTEREST)
批准号:
10012378
负责人:
Guido Ferrari
金额:
$4.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-03-06 至 2021-02-28

项目摘要

项目成果

Guido Ferrari的其他基金

相似基金

相关文献

中文摘要
翻译
抽象的。 联合国艾滋病规划署对全球艾滋病毒负担的最新估计是,3690万人 全球艾滋病毒-1感染者,其中69.4%居住在撒哈拉以南非洲。值得注意的是,三 在撒哈拉以南非洲,四分之一的新感染者是15-19岁的女孩和#岁的年轻妇女。 15-24岁感染艾滋病毒的可能性是这个年龄段男性的两倍。此外,一个显著的不同之处 存在于撒哈拉以南非洲的东部/南部和西部/中部地区之间,减少了 2010年以来与艾滋病相关的死亡人数分别为42%和24%。显然,在以下方面仍有许多工作要做 对当地医生和科学家进行诊断、治疗和管理的培训 艾滋病毒-1感染;开展实施科学,以确定资金的最具成本效益的使用 和人力资源;确保有证据的公共卫生政策和方案拟订,以减少 非洲各次区域对艾滋病的反应存在差异。尽管治疗可能对 为了减缓艾滋病毒的传播,艾滋病毒预防仍然是遏制艾滋病毒浪潮的关键。事实上,一秒钟 预计未来12年艾滋病大流行的原因是1)非洲人口结构的变化 青年人数增加,2)传播的病毒耐药性增加,3)成本和 二线和三线治疗方案的可用性有限。综上所述,这些因素表明 艾滋病病毒携带者的总人数可能每年增加200万,达到惊人的5000万 到2030年在全球范围内。 自2007年以来,13个成功的年度兴趣会议,被称为“非洲CROI”,已经 聚集了参与艾滋病毒诊断和治疗、发病机制和预防的科学家 在非洲资源有限的情况下进行研究,以分享关键发现,促进合作,以及 将经验转移到多个领域和多个大洲。规划和组织2020年 兴趣会议将由阿姆斯特丹全球卫生与发展研究所监督。 凯瑟琳·汉金斯博士是Interest国际会议委员会(ICC)主席,也是 感兴趣的科学主席。 2020年兴趣大会的主办方将追求以下目标: 1)提供诊断和治疗、发病机制、 成人,包括老年人、青少年和儿童,预防艾滋病毒-1 艾滋病毒在非洲,以促进实现90-90-90病毒抑制目标和 防止第二次大流行。 2)促进主要研究人员和代表 未来在非洲大陆医疗保健和研究方面的潜在科学领导地位。
英文摘要
Abstract. The most recent UNAIDS estimates of the global burden of HIV are that 36.9 million people are living with HIV-1 infection worldwide, with 69.4% of these residing in sub-Saharan Africa. Markedly, three in four new infections in sub-Saharan Africa are among girls aged 15–19 years and young women aged 15–24 years are twice as likely to be living with HIV than men that age. Further, a striking difference exists between the east/southern and the west/central regions of sub-Saharan Africa, with reductions in AIDS-related deaths since 2010 of 42% and 24%, respectively. Clearly, much work remains in terms of training local physicians and scientists in the diagnosis, treatment, and management of individuals with HIV-1 infection; conducting implementation science to determine the most cost-effective use of financial and human resources; and ensuring evidence-informed public health policy and programming to reduce disparities in the AIDS response across Africa’s sub-regions. Despite treatment likely having contributed to slowing HIV transmission, HIV prevention remains critical to stem the tide of HIV. In fact, a second AIDS pandemic in the next 12 years is predicted due to 1) changing demographics in Africa with increasing numbers of youth, 2) increasing transmitted viral drug resistance, and 3) increased cost and limited availability of 2nd and 3rd line treatment regimens. Taken together, these factors suggest that the total number of people living with AIDS may increase by 2 million/year to reach a staggering 50 million worldwide by 2030. Since 2007, 13 successful annual INTEREST Conferences, known as the ‘African CROI’, have brought together scientists involved in HIV diagnosis and treatment, pathogenesis, and prevention research in resource-limited settings in Africa to share pivotal findings, promote collaboration, and transfer experiences across several fields and many continents. Planning and organization of the 2020 INTEREST Conference will be overseen by the Amsterdam Institute of Global Health and Development. Catherine Hankins MD PhD chairs INTEREST’s International Conference Committee (ICC) and is the Scientific Chair of INTEREST. The organizers of the 2020 INTEREST Conference will pursue the following objectives: 1) To provide cutting-edge knowledge in the fields of diagnosis and treatment, pathogenesis, and prevention of HIV-1 for adults, including the elderly; adolescents; and children living with HIV in Africa, in order to contribute to achieving the 90-90-90 viral suppression goal and to preventing a second great pandemic. 2) To foster new research interactions among leading investigators and those who represent the potential future scientific leadership for health care and research on the African continent.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SOSIP-NP/mRNA combination for novel preventive and therapeutic HIV-1 vaccine regimens
  • 批准号:
    10696131
  • 项目类别:
  • 资助金额:
    $590.26万
  • 财政年份:
    2022
  • 负责人:
    Guido Ferrari
  • 依托单位:
SOSIP-NP/mRNA combination for novel preventive and therapeutic HIV-1 vaccine regimens
  • 批准号:
    10461584
  • 项目类别:
  • 资助金额:
    $571.99万
  • 财政年份:
    2022
  • 负责人:
    Guido Ferrari
  • 依托单位:
Linking Antibody Cooperativity and Effector Cell Engagement
  • 批准号:
    10670258
  • 项目类别:
  • 资助金额:
    $95.8万
  • 财政年份:
    2021
  • 负责人:
    Guido Ferrari
  • 依托单位:
Linking Antibody Cooperativity and Effector Cell Engagement
  • 批准号:
    10475288
  • 项目类别:
  • 资助金额:
    $95.74万
  • 财政年份:
    2021
  • 负责人:
    Guido Ferrari
  • 依托单位:
海外基金